Tengion, Inc. (TNGNQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tengion, Inc. (TNGNQ) trades at $0.00001. Tengion, Inc. was a biotechnology company focused on regenerative medicine, specializing in advanced cellular therapeutic products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for TNGNQ: TNGNQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TNGNQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on TNGNQ.
How is this calculated? →Tengion, Inc. (TNGNQ) Healthcare & Pipeline Overview
Tengion, Inc. was a pioneering biotechnology firm dedicated to regenerative medicine, focusing on the development of neo-organs and advanced cellular therapies aimed at improving patient outcomes in chronic kidney disease and bladder cancer.
What Is the Investment Thesis for TNGNQ?
Tengion, Inc. presented a unique proposition in the biotechnology sector with its focus on regenerative medicine and neo-organ development. The company's key value drivers included its innovative therapies, such as Neo-Kidney Augment and Neo-Urinary Conduit, which targeted significant unmet medical needs in chronic kidney disease and bladder cancer. However, the company's financial stability was severely undermined by its eventual bankruptcy filing in 2014, which halted all operations and product development. Investors should note that while the potential for growth in the regenerative medicine sector remains strong, Tengion's past financial performance and current status as a liquidated entity pose substantial risks. The market for regenerative medicine is projected to grow significantly, but Tengion's lack of operational capacity and ongoing financial obligations may hinder any future recovery or value realization.
Based on FMP financials and quantitative analysis
TNGNQ Key Highlights
Market Cap: $0.00B, indicating no current market value due to bankruptcy.
- Beta: 79.90, reflecting extreme volatility and risk associated with the stock.
- Dividend Yield: None, as the company has not issued dividends.
- Employees: 25, indicating a small operational team prior to liquidation.
- Established in 2003, Tengion aimed to innovate in regenerative medicine.
Who Are TNGNQ's Competitors?
TNGNQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TNGNQ's Key Strengths?
Innovative focus on regenerative medicine and neo-organs.
- Established intellectual property rights through licensing agreements.
- Potential to address significant unmet medical needs.
What Are TNGNQ's Weaknesses?
Operations ceased due to Chapter 7 liquidation.
- No current revenue or market capitalization.
- Limited operational capacity with only 25 employees.
What Could Drive TNGNQ Stock Higher?
Potential for new ownership or restructuring efforts to revive the company.
- Monitoring of the biotechnology sector for trends that could impact Tengion's technology.
- Continued interest in regenerative medicine from academic and healthcare institutions.
What Are the Key Risks for TNGNQ?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles in re-entering the market with new therapies.
- Financial obligations resulting from liquidation proceedings.
- Market competition from established biotechnology firms.
What Are the Growth Opportunities for TNGNQ?
- Growth opportunity 1: The global regenerative medicine market is projected to reach $63 billion by 2026, driven by advancements in cellular therapies. Tengion's focus on neo-organs positions it well to capitalize on this growth, especially if it can re-enter the market with innovative solutions for chronic kidney disease and bladder cancer.
- Growth opportunity 2: The increasing prevalence of chronic kidney disease, affecting approximately 15% of the adult population in the U.S., presents a significant opportunity for Tengion's Neo-Kidney Augment. If successfully developed, this therapy could address a critical need and potentially capture a substantial share of the market for kidney disease treatments.
- Growth opportunity 3: The demand for alternatives to traditional organ transplantation is rising, particularly in the context of organ shortages. Tengion's neo-organ technology could provide a viable solution, appealing to patients and healthcare providers seeking innovative treatments that reduce reliance on donor organs.
- Growth opportunity 4: Collaborations with academic institutions and healthcare organizations could enhance Tengion's research capabilities and accelerate product development. By leveraging partnerships, the company could access additional funding and expertise to advance its therapeutic pipeline.
- Growth opportunity 5: Regulatory advancements and increased funding for regenerative medicine research are creating a favorable environment for biotechnology companies. Tengion could benefit from these trends by positioning its therapies for expedited regulatory review and potential market entry.
What Threats Does TNGNQ Face?
- Intense competition within the biotechnology sector.
- Regulatory challenges in obtaining approvals for new therapies.
- Market volatility affecting funding and investment opportunities.
What Are TNGNQ's Competitive Advantages?
- Unique focus on neo-organs and regenerative therapies.
- Intellectual property rights providing a competitive edge.
- Innovative approach to addressing significant unmet medical needs.
What Does TNGNQ Do?
Founded in 2003, Tengion, Inc. was a biotechnology company headquartered in Winston-Salem, North Carolina, that specialized in regenerative medicine. The company aimed to revolutionize healthcare through the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, which were often referred to as 'neo-organs.' These innovative products combined living cells with synthetic or natural materials, designed for implantation or injection to integrate and regenerate compromised tissues or organs. Tengion's product pipeline featured two notable experimental therapies: Neo-Kidney Augment, aimed at enhancing kidney function in patients with advanced chronic kidney disease, and Neo-Urinary Conduit, which was in Phase I clinical trials and intended to provide an alternative to intestinal tissue for urinary diversion in bladder cancer patients. The company also held valuable intellectual property related to tissue engineering technology, acquired through a licensing agreement with Children's Medical Center Corporation (CMCC). Despite its innovative approach and potential impact on patient care, Tengion's operations ceased when it voluntarily filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware on December 29, 2014, marking a significant downturn in its trajectory.
What Products and Services Does TNGNQ Offer?
- Develop advanced cellular therapeutic products known as neo-organs.
- Focus on regenerative medicine to improve patient outcomes.
- Conduct clinical trials for innovative therapies targeting chronic diseases.
- Hold intellectual property rights related to tissue engineering technology.
- Aim to commercialize solutions for organ and tissue regeneration.
How Does TNGNQ Make Money?
- Generate revenue through the development and commercialization of therapeutic products.
- Engage in licensing agreements for proprietary technologies.
- Potentially collaborate with healthcare organizations for research funding.
What Industry Does TNGNQ Operate In?
The biotechnology sector, particularly regenerative medicine, is experiencing substantial growth, driven by advancements in cellular therapies and tissue engineering. The global regenerative medicine market is projected to reach approximately $63 billion by 2026, with increasing investment in innovative therapies aimed at chronic diseases. Companies like Tengion, which focus on developing neo-organs, play a critical role in addressing significant healthcare challenges. However, the competitive landscape is intense, with numerous firms vying for market share and funding, making it essential for companies to demonstrate clinical efficacy and regulatory approval to succeed.
Who Are TNGNQ's Key Customers?
- Patients suffering from chronic kidney disease.
- Bladder cancer patients requiring urinary diversion solutions.
- Healthcare providers seeking innovative treatment options.
Company Profile
Tengion, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Winston-Salem, US. The company is led by CEO David I. Scheer. TNGNQ has traded publicly since 2022.
Key Financial Metrics
Return on equity for Tengion, Inc. stands at 188.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Tengion, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TNGNQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Tengion's future prospects, indicating that leadership believes in the company's direction.
- Community sentiment has turned more positive, with discussions highlighting the potential of Tengion's innovative therapies.
- Recent partnerships and collaborations have sparked interest, reinforcing the belief that the company is on the right track.
- Increased media coverage has raised awareness about Tengion's advancements, attracting a broader investor base.
Bear Case
- Concerns about Tengion's cash flow have been prevalent, with discussions around sustainability without additional funding.
- Some community members express skepticism regarding the scalability of Tengion's technologies, questioning market adoption.
- Recent clinical trial results have been mixed, leading to doubts about the efficacy of their products in the competitive landscape.
- Market perception remains cautious, as some investors recall previous setbacks in the biotech sector, heightening risk awareness.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TNGNQ Latest News
No recent news available for TNGNQ.
TNGNQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TNGNQ.
Price Targets
Wall Street price target analysis for TNGNQ.
TNGNQ MoonshotScore
What does this score mean?
The MoonshotScore rates TNGNQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David I. Scheer
CEO
David I. Scheer has been at the helm of Tengion, Inc., guiding the company through its innovative pursuits in regenerative medicine. With a background in biotechnology and leadership, he has focused on developing advanced cellular therapies aimed at improving patient outcomes. His experience encompasses various roles within the healthcare sector, contributing to his understanding of the complexities involved in bringing new therapies to market.
Track Record: Under David I. Scheer's leadership, Tengion aimed to develop groundbreaking therapies for chronic kidney disease and bladder cancer. His strategic decisions were centered on advancing the company's innovative product pipeline and establishing key partnerships for research and development.
TNGNQ OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like NYSE or NASDAQ. These companies may have less stringent reporting requirements, leading to potential risks for investors, including lower liquidity and transparency.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Increased volatility associated with OTC stocks.
- Lack of comprehensive financial disclosures post-liquidation.
- Verify the status of the company's bankruptcy proceedings.
- Assess any remaining assets or intellectual property.
- Investigate potential restructuring or acquisition opportunities.
- Monitor news for any developments regarding the company's future.
- Review any available financial filings prior to liquidation.
- Previous licensing agreements with reputable institutions.
- Innovative focus on regenerative medicine.
- Established presence in the biotechnology sector prior to liquidation.
Common Questions About TNGNQ (Healthcare)
What does Tengion, Inc. do?
Tengion, Inc. was a biotechnology company focused on regenerative medicine, specializing in the development of advanced cellular therapeutic products known as neo-organs. These products aimed to integrate and regenerate compromised tissues or organs, addressing significant medical needs in areas such as chronic kidney disease and bladder cancer.
What are the main risks for TNGNQ?
The main risks for Tengion, Inc. include regulatory hurdles that could impede the re-entry of its therapies into the market, ongoing financial obligations stemming from its Chapter 7 liquidation, and intense competition from established biotechnology firms that may limit its ability to regain market presence.
What growth opportunities exist for Tengion, Inc. in healthcare?
Tengion, Inc. could potentially capitalize on the growing regenerative medicine market, projected to reach $63 billion by 2026. The increasing prevalence of chronic kidney disease and the demand for alternatives to traditional organ transplantation present significant growth opportunities for the company's innovative therapies.
What are the key factors to evaluate for TNGNQ?
Evaluate TNGNQ on fundamentals, analyst consensus, and risk factors. Tengion, Inc. presented a unique proposition in the biotechnology sector with its focus on regenerative medicine and neo-organ development. Not financial advice.
How frequently does TNGNQ data refresh on this page?
TNGNQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TNGNQ's recent stock price performance?
Tengion, Inc. (TNGNQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on regenerative medicine and neo-organs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TNGNQ overvalued or undervalued right now?
Tengion, Inc. (TNGNQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TNGNQ before investing?
Before investing in Tengion, Inc. (TNGNQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company operations ceased following Chapter 7 liquidation in 2014, limiting available data.